TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from BriaCell Therapeutics ( (TSE:BCT) ) is now available.
BriaCell Therapeutics has announced promising clinical biomarker data from its ongoing pivotal Phase 3 study of Bria-IMT combined with an immune checkpoint inhibitor in metastatic breast cancer. The data, presented at the ESMO Congress 2025, shows encouraging trends similar to those identified in the Phase 2 study, with no new safety concerns. The study’s positive interim results could lead to full approval and marketing authorization, potentially impacting treatment options for patients with limited choices.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$40.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care.
Average Trading Volume: 3,823
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$31.16M
For an in-depth examination of BCT stock, go to TipRanks’ Overview page.